Tag: Rnai

According to the American Heart Association, many individuals with hypertension struggle with medication adherence, a major factor in poor blood pressure control. An investigational RNA interference (RNAi) therapy, zilebesiran, is garnering attention as the potential **six monthly blood pressure injection**, offering a novel approach to address this challenge by providing long-lasting blood pressure reduction.

First approved in 2022 for hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy, **vutrisiran** (brand name Amvuttra) is a gene-silencing medication that offers a new approach to treatment. It works by targeting the root genetic cause of the disease, preventing the production of the toxic protein that causes nerve and heart damage.